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One purpose of this study was to develop a paliperidone (PAL) tri-layer ascending release
pushepull osmotic pump (TA-PPOP) tablet which could meet the needs of clinical appli-
cations. And another purpose was to investigate whether different coating materials
influenced in vivo performance of TA-PPOP. The ascending release mechanism of this tri-
layer delivery system on theory was elaborated. TA-PPOP was prepared by means of
coating with cellulose acetate (CA) or ethyl cellulose (EC). Several important influence
factors such as different core tablet compositions and different coating solution in-
gredients involved in the formulation procedure were investigated. The optimization of
formulation and process was conducted by comparing different in vitro release behaviors of
PAL. In vitro dissolution studies indicated that both the two formulations of different
coating materials were able to deliver PAL at an ascending release rate during the whole
24 h test. The in vivo pharmacokinetics study showed that both self-made PPOP tablets with
different coating had a good in vitro-in vivo correlation (IVIVC) and were bioequivalent with
the brand product, which demonstrated no significant influence of the coating materials on
the in vivo release acceleration of TA-PPOP.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).tical University, No. 103, Wenhua Road, Shenyang 110016, China. Tel./fax: þ86 24 23986321.
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As a benzisoxazole derivative, an active metabolite of risper-
idone and mediating through a combination of central dopa-
mine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor
antagonism, paliperidone (PAL) is approved by FDA for the
treatment of central nervous system (CNS) disease schizo-
phrenia [1]. Comparing to risperidone, it's an advanced
second-generation atypical antipsychotic [2,3]. Also, it's re-
ported that PAL can provide positive affective symptoms in
the treatment of adults with schizoaffective disorder [4].
Because of the multiple dosing, long administration cycle
and complicating of the treatment of CNS disease [5,6], a lot of
sustained release and controlled-release dosages are used to
ease suffering of the patients and cure the formidable disease.
One satisfying example is the osmotic pump tablet (OPT)
which drivers drug ingredients by osmotic pressure and ex-
hibits zero-order release behavior. Besides, the release kinetic
is only rest with the osmotic pressure of the system and free
from the release medium pH, stirring speed and gastrointes-
tinal peristalsis [7]. Rose and Nelson designed a simple long-
term injector which was capable of delivering fluid at a con-
stant rate for a long time in 1955. This was the rudiment of the
osmotic pump [8]. ALZA pharmaceutical company developed
the elementary osmotic pump (EOP) [9] to deliver water-
soluble drugs via osmotic pressure and then Theeuwes and
Higuchi [10] elaborated the basic principle of the osmotic
pump in the 1970s. According to the Biopharmaceutical
Classification System (BCS), Class II drugs possess the char-
acteristics of high permeability and poor solubility. In order to
achieve a high pressure and procure a smooth release for the
poor solubility drugs such as the former model drug PAL,
Malaterre carried out the pushepull osmotic pump (PPOP) [11]
which consisted of a bi-layer core surrounded by a semi-
permeable membrane with a laser-drilled orifice. The boost
layer polymer swelled and the drug suspensionwas driven out
through the release orifice.
However, this kind of simple zero-order release dosage
form still cannot settle the root curing dilemma upon the CNS
drugs. Firstly, the therapeutic process requires dosage titration
considering different patients with the same kind of CNS dis-
ease have changed dosage need. It's clear that dosage titration
is often utilized in the individualized treatment of reliving
cancer-related breakthrough pain which is a challenging
clinical phenomenon [12]. As to CNS drugs, on one hand,
dosage titration can avoid the dosage is too low, which
resulting in the curingprocess in vain; on the otherhand, it can
decrease the adverse effect [13]. Secondly, acute tolerance
often shows up after the CNS drugs are administered to pa-
tients [14]. Thirdly, a series of adverse effects will take place
during the treatment ofCNSdisease [15].Moreover, sideeffects
will often decrease a patient's willingness to adhere to treat-
ment while physical and psychiatric comorbidities add to the
complexity of treatment [16]. So, it's urgent to develop some
kinds of non-zero order release dosages of PPOP to work
around this issue. In recent years, ascending release [17],
delayed sustained-release [18] and sandwich-shaped [19] PPOP
have been exhibited by the researchers. Among these,
ascending release PPOP showed great advantages which couldnot only provide a steady and slow drug release rate avoiding
thehigh initialplasmaconcentration tokeepeffective, tolerant
andsafe, but alsomaintainasmooth, controlledandprolonged
therapeutic window decreasing the adverse effects and drug
excitation and improving the compliance [20]. The commercial
product Invega® (3 mg) [21] whichwas chosen as the reference
preparation in this study is a tri-layer ascending release tablet.
Heming Xu [22] had found a proper kind of polyethylene
oxide and developed a novel bi-layer ascending release
osmotic pump tablet. It differed a lot with the commercial
product on the tablet structure and the manufacture process
was easier. The study explained the key point to achieve non-
zero order drug release rate of bi-layer osmotic pump tablet on
theoretical analysis. In order to observe thehydration status of
the drug layers the author cut the tablet into halves and pho-
tographed them.Also, the author designed a small experiment
to further estimate the influence of the orifice size on drug
release. Thesewere the characteristics of this study. However,
the paper had some drawbacks. Firstly, influences of coating
solution ingredients involved with important factors were not
taken into concern. Secondly, the determination method of
plasma paliperidone concentration was performed by HPLC,
which was not accurate. Thirdly, concentrationetime profiles
of paliperidone in plasma showed the peak plasma concen-
tration was about 80 mg/ml, which was unauthentic and likely
to the unit of ng/ml. So, to solve these issues andmake further
investigation to the osmotic pump tablet, this study developed
an extremely similar tri-layer ascending release tablet to the
commercial one as a me-too drug. Comparing to the investi-
gation of Xu, different core tablet, different manufacture pro-
cess, different release theory and diverse in vivo experimental
design and evaluation were performed. Particularly, we
investigated the influences of coating solution ingredients and
applied UPLC-MS/MSmethod to preciselymeasure the plasma
concentration and made comparison to different coating ma-
terial. These were the advantages and progress in the study.
When it comes to the coating of OPT, different semi-
permeablemembranes coatingmaterials are alternative, such
as cellulose acetate and ethyl cellulose. The semipermeable
membrane is an important aspect of the osmotic pump thanks
to its role upon controlling the permeation rate of the water.
Assumption that the same core tablets are prepared and
coated with cellulose acetate and ethyl cellulose, respectively.
Also, the in vitrodissolution behaviors of the two tablets are the
same. Whether in vivo pharmacokinetics of them will still be
the same? In this paper, we attempt to answer this question.
This study exploited two distinct kinds of coating tablets:
formulation 1 was tri-layer core tablets coating by cellulose
acetate (CA); formulation 2 was tri-layer core tablets coating
by ethyl cellulose (EC). The theory of tri-layer ascending
release PPOP, in vitro evaluation, in vivo pharmacokinetics
study and IVIVC of the two formulations were investigated.2. Materials and methods
2.1. Materials
Paliperidone (PAL) was synthesized by pharmaceutical
chemistry laboratory of Shenyang pharmaceutical university.
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extended-release tablets Invega® (3 mg) which acted as the
reference preparation in this study were purchased from
Janssen Cilag Manufacturing L.L.C. (Xian-janssen, China).
Povidone K30, Hydroxy-propyl methyl cellulose (HPMC),
magnesium stearate were bought from Anhui Shanhe Pharm.
S.P.A. (Anhui, China). Polyethylene oxide (PEO) was a gift from
Dow Chemical Co., Ltd. (New Jersey, USA). Cellulose acetate
(CA) was from Sinopharm Chemical Reagent Co., Ltd.
(Shanghai, China). Ethyl cellulose (EC) was from Tianjin Bodi
Chemical Co., Ltd. (Tianjin, China). Acetone, ethanol and
polyethylene glycol 1500 (PEG 1500) were purchased from
Yuwang Chemical Reagent Co., Ltd. (Shandong, China).
Lactosemonohydrate was fromMEGGLE Co., Ltd. (Wasserburg
am Inn, Germany). Sodium chloride (NaCl) and ammonium
formate were analytical grade. UPLC-grade methanol was
purchased from Fisher Scientific (Pittsburgh, PA).
2.2. Design and theory of tri-layer ascending release oral
osmotic tablet
The TA-PPOP delivery system was designed to be a capsule-
shaped tablet [23]. It consisted of an osmotically active tri-
layer core containing two different drug concentration
layers (the first drug layer and the second drug layer) and an
osmotic push layer, surrounded by an ethyl cellulose or cel-
lulose acetate semipermeable membrane. Drug was released
through a laser-drilled hole which stands on the first drug
layer dome of the tablet. In the aqueous environment of the
gastrointestinal tract (GIT), water is imbibed by osmosis ac-
tivity gradient which controlled by osmotic excipients across
the semipermeable membrane into the system core. The
composition and thickness of themembrane also determined
the rate of water absorbed to the core. Then the drug layers
were hydrated becoming a gel-like suspension and the push
layer started to swell at the same time. As a result, the drugs
were driven out through the orifice by the expanding bottom
layer.
A theory can be used to describe the drug releasing process
[24e26]. Generally, the drug release rate ðdm=dtÞ of a single
drug core and the volume imbibition rate of water ðdv=dtÞ of
oral osmotic tablet can be described like this:
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where Cs is the mass concentration of the drug in suspension,
A is the membrane area, k is the osmotic membrane perme-
ability, h is the membrane thickness, p is the osmotic
pressure.
As to a multicompartment core oral osmotic tablet,
different drug layers have various drug concentrations. So the
mass release rate should be calculated by this equation:
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where n represents the number of the drug layer. In this
multicompartment system, the bottom layer acts as the push
layer which contains no drug (C1 ¼ 0). Subsequent layers
maybe have different drug concentrations (C2s C3s…s Cn).
Different release profiles will be achieved if the drug suspen-
sions from these layers are drove out continuously. For
instance, when C1 ¼ 0 and C2 ¼ C3 ¼ Cn, zero order release
kinetics will be got. When C1 ¼ 0 and C2 > C3 > Cn, ascending
release kinetics will be performed. When C1 ¼ 0 and
C2 < C3 < Cn, descending release kinetics will be generated.
As to the tri-layer ascending release oral osmotic tablet
(TA-PPOP) in this study, n equals three. Andwe design the first
drug layer containing a lower drug concentration than the
second layer, which provides the necessary concentration
gradient to achieve a gradual but ascending release of the
drug. Here C2 > C3. The time goes by. The first drug layer is
pushed out firstly. After most of the drug is released from the
first compartment, drug release begins from the second
compartment at an ascending releasing rate.
Take each single drug layer into consideration, the drug
release rate of the two layers are calculated as follows:
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where ðdm=dtÞ3 and ðdm=dtÞ2 stands for the drug release rate of
the first drug layer and the second drug layer, respectively.
Ignoring other factors, it can infer that ðdv=dtÞ3zðdv=dtÞ2.
Adding C2 > C3, throughout the whole 24 h releasing period,
releasing rate of the first layer and the second layer can be
displayed as follows:

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(7)
So, as a result, tri-layer oral osmotic tablet designed by this
shape and this composition can achieve an ascending drug
release rate to become TA-PPOP.2.3. Preparation of the formulations
The formulation of core tablets was consisted of paliperidone,
Povidone K30, Hydroxy-propyl methyl cellulose, magnesium
stearate, polyethylene oxide, lactose monohydrate, sodium
chloride, butylated hydroxytoluene, stearic acid and iron ox-
ides. Details see Table 1.
Active pharmaceutical ingredient (API) PAL and all the ex-
cipients were passed through 80-mesh sieve before use,
respectively. The first drug layer blend was prepared by mixing
PAL and other excipients in a sealed polyethylene bag. The sec-
ond drug layer blend was prepared by mixing a different per-
centage of PAL and certain excipients in the same kind of bag.
Thethirddrug layer (push layer)blendwasestablishedbymixing
Table 1 e The composition of core tablets.
Composition of the first drug
layer
Paliperidone
Polyethylene oxide
Osmotic agent
Stearic acid
Composition of the second
drug layer
Paliperidone
Polyethylene oxide
Stearic acid
Composition of the push layer Hydroxy-propyl methyl cellulose
Povidone K30
Osmotic agent
Iron oxides
Magnesium stearate
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formerly were operated by hand for 15 min to obtain a homo-
geneous physical mixture. Then, by preparing a damp mass,
screening the dampmass into granules, drying the granulation,
sizing the granulation through dry screening, adding lubricant
and blending, the wet granulation process was accomplished.
Core tablets were compressed by a single-punch tablet
machine equipped with a particular shallow recessed punch
(5mmdiameter) (TDP single-punch, Shanghai Pharmaceutical
Factory, China). The compress process was as follows: Firstly,
all the three layers were accurately weighted, respectively;
secondly, the first drug layer powder was loaded and pre-
compressed manually; thirdly, the second layer drug powder
was loaded and pre-compressed as the same way; finally, the
push layer powder was added into the punch groove and
compressed into tri-layer tablets.
We prepared two separate kinds of coating tablets:
formulation 1 was tri-layer core tablets coating by cellulose
acetate (CA); formulation 2 was tri-layer core tablets coating
by ethyl cellulose (EC). The coating solution of formulation 1
was developed by dissolving cellulose acetate and/or PEG 1500
into a precise percentage of acetone-water. The coating so-
lution of formulation 2 was developed by dissolving ethyl
cellulose and/or PVP K30 in some kind percentage of alcohol-
water. The two kinds of formulations were coated both by a
traditional coating pan (BY300A, Shanghai Huanghai Ma-
chinery Factory, Shanghai, China). Drying temperature was
set at about 32～42 C, rotating rate of the panwas 40～45 rpm,
spraying rate was 5ml/min. Under this circumstance, the core
tablets were sprayed and covered a homogeneous coating
membrane of dissimilar material, respectively. To clear away
the residual solvent and aging the membrane, the coating
tablets were dried for 10 h at 40 C in the oven.
Drug release orifice was drilled by hand by using a kind of
twist-drill. We purchased a series of different sizes of the
twist-drills (Dongguan Shunjia hardware Machinery Factory,
Dongguan, China) and we can obtain the diameter from the
specification so that we could drill some needed orifices.
2.4. In vitro dissolution test
In vitro dissolution testwas accomplished at 37± 0.5 C, 50 rpm
according to the USP paddle method [27]. To preventing the
tablets floating on the surface of the medium after releasing
all the drugs, sinkerswas used in the experiment. The testwasoperated by using a dissolution apparatus (ZRS-8G Test
Dissolution Tester, China). A volume of 500 ml NaCl 2 gm/L
(0.2% w/w) in 0.0825 mol/L HCl (pH 1.0 ± 0.5) was picked as the
dissolution medium. In consideration of decreasing the rela-
tive error and keeping the precision of the experiments, pre-
pared tablets (formulation 1 and formulation 2) wereweighted
to be equivalent to 3 mg of PAL as well as the marketed
Invega®. Then they were added into the dissolution medium
respectively at the same time. A volumeof 10ml sampleswere
withdrawn after 2, 4, 8, 12, 14 and 24 h and reinstated by equal
volume of fresh medium synchronously to sustain the speci-
fied volume of themedium. The sampleswere filtered through
a 0.45 mm millipore filter and analyzed by HPLC.
TheanalysiswascarriedoutbyanHPLCsystemconsistingof
a CM-5110 pump, a CM-5210 auto-sampler, a CM-5310 column
ovenmaintained at 35 C, a CM-5410/5420 UVeVIS detector set
at 275 nm and Chromaster workstation (Hitachi, Japan). Before
the test, a methodological study was carried out. The results
indicated there was no interference in UV absorption between
the excipients and the drug and the analytic method satisfied
the requirements of the concentrations determination of sam-
ples ranging from 2 to 24 h. The separations were performed at
roomtemperaturebyusingaC18 column (4.6 150mm,particle
size 5 mm, Huapu Co., Ltd., China). The mobile phase was
0.05 mol/L ammonium formate buffer solution (pH 3.3 ± 0.1)
acetonitrile-methanol (75:8:17, v/v), pumped at a flow rate of
1.5 ml/min. They were filtered through a 0.45 mm membrane
filter and degassed by ultrasonication before use.
Both of marketed Invega® and prepared formulations
(formulation 1 and formulation 2) showed an ascending drug
release rate. To evaluate this release behavior, we chose the
similarity factor (f2). The calculation formula was character-
ized as follows [28]:
f2 ¼ 50 log
("
1þ 1
n
Xn
i¼1
ðRt  TtÞ2
#0:5
 100
)
wherein n stands for the numbers of the samples, Rt and Tt
represents the drug release percentages of the marketed
Invega® and prepared formulation 1 and formulation 2 at time
t, respectively. We admitted that the two drug release dates
were the same as each other if the similarity factor (f2) was
between 50 and 100.2.5. In vivo evaluation
2.5.1. Experimental design
Six healthy beagle dogs (General Hospital of ShenyangMilitary
Region, China) were chosen. This study was performed in
accordance with the “Guiding Principles in the Use of Animals
in Toxicology” [29] adopted by the Society of Toxicology of the
US in July 1989 and revised in March 1999. A 3-period cross-
over single-dose with a washout period in between experi-
ment was designed. All the dogs were fasted overnight and
free of water prior to the experiments. Six dogs were sepa-
rated into three groups randomly and preparations (reference
marketed Invega®, formulation 1 and formulation 2) contain-
ing 6 mg (each dog gives 2 tablets) of PLA were administered
to the three groups, respectively. During the whole in vivo
experiments, 5 ml of blood sample were withdrawn in
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22, 24, 26, 30, 32, 36, 48, 60, 72, 84, 96 h after dosing. All the
samples were centrifuged immediately at 3000 rpm for 15 min
to get the separated plasma. Then the plasmawas kept frozen
at 20 C until analysis.
2.5.2. Determination of paliperidone in dog plasma
The determinationwas performed by using ultra performance
liquidchromatography-tandemmassspectrometry (UPLC-MS/
MS)with aWaters TandemQuadrupole (TQ)Detector (Waters).
According to the investigation of Hongming Chen, diazepam
(DIA) was chosen as the internal standard. The separationwas
conducted on a C18 column (50 2.1mm, 2.6 mm; Phenomenex
Co.,USA)at 40 C.Themobilephasewaswater (containing0.1%
formicacid)andmethanolataflowrateof 0.3ml/min. Injection
volume was 5 ml. UV detector was set at 275 nm [30].
Plasma sample preparation method was as follows: 200 ml
plasma was first added. Then 50 ml internal standard solution
DIA (500 ng/ml) and 50 ml methanol were added. They were
mixed by vortex for 1 min to be homogeneous. To extract the
drugs, 2 ml redistilled diethyl ether was then added to the
mixture. After vortex-mixing for 3 min, the samples were
centrifuged at 3500 rpm for 10 min. The supernatant was
collected and dried at 37 C under a stable stream of nitrogen.
Theextractionsampleswere reconstitutedby100mlmethanol-
water when they were to be determined [30]. The concentra-
tion of PAL was determined by a standard linear calibration
curve in the concentration rangeof 1e1000ng/ml (r> 0.99). The
lower limit of quantification (LLOQ）for PAL was 1 ng/ml.
2.5.3. Pharmacokinetic data analysis
With the calculation of DAS2.1.1 software (Mathematical
Pharmacology Professional Communities of China, Shanghai,
China), a series of pharmacokinetics parameters were ob-
tained, which including the peak plasma concentration (Cmax),
the time to reach peak plasma concentration (Tmax), the area
under the curve from 0 to 96 h (AUC0e96), the area under the
plasma concentrationetime curve from zero to infinity
(AUC0∞). The value of each formulation was the mean values
of the six dogs. The relative bioavailability (F) [31] of formu-
lation 1 and formulation 2 to the reference tablets (Invega®)
was calculated using the following equation: F (%) ¼ (AUC0e96
test/AUC0e96 reference)  100%. Verge for differences to be
considered significant was defined at p value <0.05.
2.5.4. In vitroein vivo correlations (IVIVC) evaluation
An IVIVC for paliperidone was evaluated by plotting the
fraction dissolved (Ft) in vitro versus the fraction of drug
absorbed ðFaÞ in vivo. Fa was calculated according to the
WagnereNelson model [32]:
Fa ¼
Ct þ ke
Z t
0
Ctdt
ke
Z ∞
0
Ctdt
 100%
whereCt is the drug plasma concentration at time t;
Z t
0
Ctdt are
areas under the curve from time zero to t;
Z ∞
0
Ctdt are areas
under thecurve fromtimezero to infinity；ke is theeliminationrate. Linear regression analysis was conducted and the coeffi-
cient correlation (r2) was used to evaluate the IVIVC.3. Results and discussion
3.1. Influence of different core tablet compositions of
tri-layer tablet (coating by CA)
In order to obtain the optimal formulation, distinctive com-
positions of the core tablet and relevant in vitro release
behavior were investigated. We concluded that the molecular
weight (Mw) of PEO, the amount of PEO in drug containing
layer and the amount of NaCl in the push layer significantly
affected the in vitro PAL release performances. It was showed
in the Fig. 1A that the drug release rate was greatly influenced
by the Mw of PEO. Because of the poor solubility of PAL, it was
difficult to form the drug suspension in the osmotic pump
without adaptive polymer materials which could avoid the
precipitation and separation of the drug after the hydration of
the drug layer.Mwof PEO from200,000, 300,000 to 400,000were
chosen in this study. The result showed the highest release
rate was achieved and the dissolution within 24 h was com-
plete when using PEO (Mw 200,000). Along with the Mw of PEO
in drug containing layer increased, the releasing rate was
decreased and the dissolution was not outright. This was
because the higher the Mw of PEO in drug containing layer
was, the larger amount of water was needed to reach the
hydration of the drug layer. When the volume imbibition rate
of water was constant, the PEO (Mw 400,000) required longer
time to suspend the drug layer. What's more, the viscosity of
PAL suspension increased, resulting in an extremely slow
releasing rate. Taking these reasons into consideration, we
picked the Mw 200,000 as the polymer suspension. The influ-
ence of the amount of PEO in drug containing layer was
demonstrated in Fig. 1B. The drug releasing rate rose and the
dissolution at 24 hwas complete alongwith the increase of the
amount of PEO. The drug could not be suspended entirely with
a small quantity of PEO. Under that circumstance, the drug
was tackled in the coating membrane and the membrane was
deformed even though the push force of the bottom layer was
constant. It was clear that osmotic pump release drugs by the
osmotic pressure. Different amount ofNaClwhich acted as the
osmotic agent in the push layer showed different in vitro PAL
release behaviors (Fig. 1C). Appropriate quantity of the osmotic
agent could achieve an ascending osmotic pressure gradient
across the membrane. PAL was pushed out too fast through
the orifices if the amount of NaClwas too highwhile therewas
not enough power to push itself out of the orifice at an
ascending rate totally if the quantity of NaCl was too low. The
hydration and expanding rate of the push layer was affected
upon the osmotic agent. In this approach, an ideal ascending
releasing rate could obtain by regulating the osmotic agent.
3.2. Influence of the coating of tri-layer tablet
3.2.1. Influence of the water amount in the coating solution
(coating by CA)
It was observed in Fig. 1D that water amount in the coating
solution influenced the ascending release considerably. The
Fig. 1 e The effect of molecular weight of PEO in drug layer (A), amount of PEO in drug layer (B), amount of NaCl in push layer
(C) and amount of water in coating solution (D) on in vitro drug ascending release profiles.
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gradually when the water amount in the coating solution
went down. The solution was prepared by dissolving cellulose
acetate and PEG 1500 which used as the porogen into the
acetone-water. PEG 1500 and the water would help forming
the porous film structure during the coating process. If larger
amount of water was added to the coating solution, the film
structure would become more porous. Thus, the volume
imbibition rate of water increased, which resulting in faster
hydration rates of push layer and drug layer and thereby
faster ascending drug releasing rate. However, the maximal
amount of water of the coating solution was limited because
the cellulose acetate would not dissolve in the acetone-water
solution completely when there were too many hydrophilic
solvents.
3.2.2. Influence of the Mw of PEG in the coating solution
(coating by CA)
It was showed in Fig. 2A that the ascending releasing rate was
significantly influenced by the Mw of PEG. The releasing rate
was also decreased along with the Mw of PEG in the coating
solution reduced. Generally, proper additive ingredient was
needed to be added into the coating solution. On one hand, it
could aggrandize toughness and strength of the coating
membrane; on the other hand, it could adjust the permeability
of the film to achieve the requested drug releasing rate. The
study chose PEG because it was water-soluble and could reach
these requires. The PEG was homogeneously dispersed in the
coating solution and coated surrounding the core tables with
cellulose acetate after being sprayed. It was well known that
HOCH2 (CH2OCH2)m CH2OH represented the molecular for-
mula of PEG, where m represented the average number of
oxyethylene groups. Mw of PEG was related to the m value. A
higherMwwas accompanied with a biggerm value. Due to thewater-solubility of PEG which was caused by oxyethylene
groups, higher Mw of PEG could present more water-soluble
and obtain more porous film structure. Lots of pores were
formed when the tablets were dried. As a result, the tablet
with PEG 6000 achieved the highest ascending releasing rate.
But we did not hope the drug been driven out too fast. So PEG
1500 was chosen to add into the coating solution in the end.
3.2.3. Influence of the amount of PEG of in the coating
solution (coating by CA)
Different amount of PEG in the coating solution would cause a
variety drug releasing rate (Fig. 2B). It could conclude that the
drug was driven out faster at an ascending releasing rate if a
larger quantity of PEG was added into the coating solution.
The drug would be released slowly and even could not be
pushed out completely when the PEG component was not
enough. It was clear that the water amount in the coating
solution influenced the ascending release considerably. PEG
was used to form a porous film structure and the water was
used to dissolve this kind of porogen. So there was a similarity
between the two factors. Both of them could enhance the
permeability of the membrane. In this study, very little water
could infiltrate through the membrane into the core tablet
when 0.02 g PEG was used. Thereby, neither the drug layer nor
the push layer could receive an abundant impetus to drive out
the drugs. So, an appropriate ascending releasing rate could
obtain by adjusting the amount of PEG in the coating solution.
3.2.4. Influence of coating weight gain of tri-layer tablet
(coating by CA)
Fig. 2C described ascending releasing behavior of PAL from the
tri-layer PPOP tablets with different coating weight gain. The
result indicated that the ascending releasing rate was affected
by the coating weight gain. It was evident to find that the drug
Fig. 3 e In vitro drug ascending release profiles of
formulation 1, formulation 2 and the reference preparation.
Fig. 2 e The effect of molecular weight of PEG in the coating solution (A), amount of PEG in the coating solution (B), coating
weight gain (C) and size of the orifice (D) on in vitro drug ascending release profiles.
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coating weight gain went up. The coating membrane was
utilized to control the penetration rate of the water between
the core tablet and the gastrointestinal tract environment.
Water penetration decreased if the coating weight gain
increased and the hydration of the drug layer and the push
layer became slower, resulting in the decline of the ascending
releasing rate. Therefore, the coating weight gain was a
particularly important factor to the osmotic pump tablets. On
one hand, it would be hard to drive out the drugs from the
orifice and release completely when the coating membrane
was too thick. The whole releasing process would be affected
owing to the lack of enough push forces under a low pene-
tration of water, especially the end stage of the drug releasing.
On the other hand, the coating membrane was inclined to
weaker with a smaller thickness, resulting in a much more
rapid ascending drug release rate and even an easier break of
the film against the enormous push impetus caused by the
osmotic pressure.
3.2.5. Influence of different sizes of the orifices of tri-layer
tablet (coating by CA)
Fig. 2D indicated that no significant influence of different sizes
of the orifices on the ascending releasing behavior. Three
different kinds of tablets were prepared and the sizes of the
orifices varied from 0.5 mm, 0.8 mme1.0 mm. The dissolution
of the tablets with different sizes of orifices displayed similar
profiles (f2 > 50). It could conclude from the figure that the root
drug driven force of the osmotic pump came from the osmotic
pressure across the membrane. Although the sizes of the or-
ifices were distinctive, the drug releasing rate was constant.
The orifice was just used to let the drug been expelled.
Comparing to the huge influence of osmotic pressure, the size
of the orifice could not be taken into account.3.3. Ascending drug release behavior of the formulation
1, formulation 2 and the reference preparation
The dissolution of three different formulations was studied in
the Fig. 3. Tri-layer core tablets were prepared first. Formula-
tion 1 was tri-layer core tablets coating by cellulose acetate
(CA) while formulation 2 was ethyl cellulose (EC) coating. The
coating solution of formulation 1 was developed by dissolving
cellulose acetate and PEG 1500 into acetone-water. The
coating solution of formulation 2 was developed by dissolving
ethyl cellulose and PVP K30 into alcohol-water. The exten-
sional coating solution composed of cellulose acetate and
ethyl cellulose were made by formula as showed in Table 2.
Fig. 3 described the release behavior of PAL from the three
different formulations. It was obvious that the CA coating and
EC coating tri-layer ascending releasing osmotic pump tablets
had similar in vitro dissolution behavior. Also, they displayed
similar profiles with the reference preparation.
Table 2 e The composition of coating solution
(formulation 1 and formulation 2).
Ingredient Amount
Formulation 1 CA 29.95 g
PEG 1500 0.05 g
Acetoneewater 1000 ml
Formulation 2 EC 28 g
PVP K30 13 g
Alcoholewater 1000 ml
Fig. 4 e In vivo pharmacokinetics profiles of PAL in beagle
dogs of reference preparation and the two self-made
formulations with different coating material (n ¼ 6).
Fig. 5 e Fraction absorbed in vivo versus fraction dissolved
in vitro of formulation 1.
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The PAL plasma concentrationetime profiles of two different
coating POPP tablets and commercial reference tablets in
beagle dogs were listed in Fig. 4. The main pharmacokinetic
parameters of PAL were shown in Table 3. It was showed that
the release profiles of both the CA coating and EC coating PPOP
reached the peak plasma concentration level at about 18.6 h
after dosing while the reference tablet was at about 20 h. The
PAL plasma concentration was increased steadily until
reaching to the highest level, and then the plasma concen-
tration decreased gradually in a prolong period which showed
a perfect ascending releasing behavior and sustained-
releasing function. The relative bioavailability of the two
self-made formulations was 115.5% (CA coating) and 119.4%
(EC coating), respectively. It was concluded from the result
that the in vivo pharmacokinetics of the two different coating
materials of TA-PPOP were still similar. No significant influ-
ence of the coating materials on the release acceleration was
found.Table 3 e Pharmacokinetic parameters of three PAL tablets (n
Parameter Unit Reference
Cmax ng/ml 63.4 ± 46.7
Tmax h 20.0 ± 1.3
AUC(0et) ng/ml*h 1399.3 ± 1189.4
AUC(0e∞) ng/ml*h 1421.7 ± 1195.4
F % 100.0So, the hypothesis in the introduction was correct and
could be proved. In this study, drug release motive power was
mainly came from the osmotic pressure of the pump and push
force of the push layer. The content of drug in each tablet was
very small and was released into the outer system for
extremely long time to continue to 24 h. It could infer that the
drug would be absorbed and metabolism immediately as long
as the drug was released into the gastrointestinal tract. Both
the two coating materials acted as the semipermeable mem-
branes. They would still keep their characteristics and func-
tions as before when the residual tablets were excreted from
the body because they were neither dissolved nor absorbed
by the bio-system. CA or EC coating materials were only acted
as carrier, as a result they had no significant influence upon
in vivo performance for paliperidone tri-layer ascending
release osmotic pump tablet.
A level A of IVIVC, point-to-point relationship [11] was
performed. The results of linear regression between in vitro
dissolution and in vivo absorption for the two self-made for-
mulations were displayed in Figs. 5 and 6. It was showed that
both of the CA coating and EC coating tablets had an excellent
linearity with r2 being 0.9914 and 0.9963, respectively. So, it
was concluded that there was a close correlation between the
in vitro dissolution and in vivo absorption.4. Conclusion
A TA-PPOP which could drive out drugs at an ascending
releasing rate and deal with complicated therapy issues of the
CNS drugs was developed in this study. Themechanism of the¼ 6).
Formulation 1 Formulation 2
65.4 ± 28.3 66.3 ± 39.9
18.7 ± 1.6 18.6 ± 1.0
1352.2 ± 648.0 1637.0 ± 1290.0
1361.5 ± 650.7 1667.8 ± 1321.2
115.5 119.4
Fig. 6 e Fraction absorbed in vivo versus fraction dissolved
in vitro of formulation 2.
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PPOP with different releasing behavior could be worked out
by adjusting drug loading in different layers. A series of
influencing factors were investigated. It was observed that the
molecular weight of PEO, the amount of PEO in drug con-
taining layer, the amount of NaCl in the push layer, water
amount in the coating solution, the molecular weight of PEG,
the amount of PEG in the coating solution and coating weight
gain significantly affected the in vitro PAL release perfor-
mances. CA coating and EC coating tablets were prepared and
the in vitro dissolution test showed both similar to the self-
made tablets and the reference preparation. The in vivo
pharmacokinetics study demonstrated that both self-made
PPOP tablets with different coating could obviously control
the release rate of PALwith a good IVIVC, which demonstrated
no significant influence of the coatingmaterials on the release
acceleration of TA-PPOP.Moreover, the two kinds of self-made
PPOP tabletswere bioequivalentwith the brand product. Thus,
this TA-PPOP model has great potential in the CNS drugs'
development.r e f e r e n c e s
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